	US 12,215,317 B2
	Acetylated ribonucleic acids and uses thereof
Nikhil Dhar, Boston, MA (US); Kyle Backman, Maynard, MA (US); Dario de Jesus Davila Pasillas, Somerville, MA (US); Justin Sean Huang, Jamaica Plain, MA (US); and Nikolai Eroshenko, Boston, MA (US)
Assigned to Helix Nanotechnologies Inc, Boston, MA (US)
Filed by Helix Nanotechnologies Inc., Boston, MA (US)
Filed on May 4, 2023, as Appl. No. 18/143,533.
Claims priority of provisional application 63/338,429, filed on May 4, 2022.
Prior Publication US 2023/0383287 A1, Nov. 30, 2023
Int. Cl. C12N 15/11 (2006.01); C07H 13/04 (2006.01); C07H 19/10 (2006.01); C07H 19/16 (2006.01); C07H 19/20 (2006.01)

CPC C12N 15/11 (2013.01) [C07H 13/04 (2013.01); C07H 19/10 (2013.01); C07H 19/16 (2013.01); C07H 19/20 (2013.01); C12N 2310/321 (2013.01)]

26 Claims

1. A polyribonucleotide comprising one or more modified ribonucleotides, wherein the one or more modified ribonucleotides comprise:

(i) a 5′-monophosphate, and

(ii) a nucleoside comprising a 2′-O-acetylated ribose and a nucleobase,

wherein the nucleobase is an adenine, a guanine, a cytosine, or an uracil, and

wherein at least 80% of the ribose moieties of the polyribonucleotide are 2′-O-acetylated, and wherein the polyribonucleotide comprises a cap structure and the cap structure does not comprise a 2′-O-acetylated ribose.